DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Pediatrics
SEARCH
Current Location:
>
> This Story


Log in or Register to rate this News Story
Forward Printable StoryPrint Comment
advertisement

 

advertisement

 

More Industry Headlines

Understanding the value of data analytics in HTM Helps with purchasing, keeping inventory of equipment, end-of-life decisions for devices

Radiologist hit with $11.5 million malpractice verdict Found negligent for missing enlarged heart diagnosis in 2009

Installing and removing imaging equipment is no small task Expert insights on how project management is evolving

Servicing vs. remanufacturing: finding the balance between safety and value at AAMI Experts weigh in on FDA white paper and ongoing debate

How important is protecting the patient health information (PHI) to your vendors? Outsourcing services comes with risks that must be addressed

Canon, Toshiba each hit with $2.5 million fine over acquisition deal Deal violated premerger notification and waiting period requirements

NYC proton facility opens for business $300 million dollar, 140,000 square-foot facility was ten years in the making

New algorithm better predictor of readmission following discharge, says study Final model drew predictions from 382 variables

US suppliers to join the Mo-99 market, high-energy materials gaining traction Radiopharmaceutical supply chain update

EQ2 showcases advancements and new products at AAMI Exchange Added data analytics, supply chain management and tracking capabilities

BARDA's $60M plan to protect against radiation poisoning

by Brendon Nafziger , DOTmed News Associate Editor
Federal officials announced they were funding the development of five drugs designed to protect people from the horrors of radiation poisoning. The government's also financing studies to develop an improved version of another drug to treat people exposed to radioactive particles that could be released during a so-called dirty bomb attack.

Biomedical Advanced Research and Development Authority, or BARDA, a division of the Department of Health and Human Services, announced the roughly $60 million in funding in a series of releases Wednesday and Thursday.

Story Continues Below Advertisement

RaySafe helps you avoid unnecessary radiation

RaySafe solutions are designed to minimize the need for user interaction, bringing unprecedented simplicity & usability to the X-ray room. We're committed to establishing a radiation safety culture wherever technicians & medical staff encounter radiation.



About $56.3 million will go toward five contracts for a variety of drug companies and scientists working on countermeasures for acute radiation syndrome, or radiation sickness. When exposed to high doses of ionizing radiation -- such as from a nuclear bomb blast -- fast-reproducing cells in the gut, bone marrow, and lungs can be destroyed, which can in turn lead to internal bleeding, a depressed immune system and death over the following days or even weeks.

Winners of contracts include Neumedicines Inc., which got a $17 million award to study recombinant human interleukin-12 (rhuIL-12). Also called HemaMax, a 2008 BARDA-funded study showed it might be able to protect bone marrow from radiation.

Johnson City, Tenn.-based RxBio Inc. nabbed a two-year, $15 million contract to study Rx100, a small molecule-drug which might be able to prevent cells in the gut from dying if administered up to three days after radiation exposure. As with many of these radioprotectants under investigation, the company also said the proprietary substance -- which it says can be stored at room temperature and has a long shelf-life -- could help reduce GI chemotherapy side effects.

University of Arkansas for Medical Sciences also got a contract to research a drug, SOM230 or pasireotide, to protect the gut from radiation. The two-year, $4.5 million contract covers research on the substance, an analog of the hormone somatostatin, which was developed by pharama giant Novartis to treat various endrocrine tumors and Cushing's disease, a condition caused by the body's over-production of cortisol. The university researchers will try to provide results that Novartis can use to submit a Food and Drug Administration application for the drug, which apparently works by preventing pancreatic secretions that inflame the intestines.

Under a two-year, $3.1 million contract, Araim Pharmaceuticals, an Ossining, N.Y.-based biotech startup, will see if its drug, ARA 290, could help save lives up to 24 hours after radiation exposure. In tests on animals, the substance, which mimics a hormone found in the body and prevents cell death and inflammation, was found to protect against lethal doses of radiation, as well as to speed up wound healing, reduce brain, kidney and heart injuries from trauma or disease, and even improve learning.
  Pages: 1 - 2 >>

Related:


You Must Be Logged In To Post A Comment

Advertise
Increase Your
Brand Awareness
Auctions + Private Sales
Get The
Best Price
Buy Equipment/Parts
Find The
Lowest Price
Daily News
Read The
Latest News
Directory
Browse All
DOTmed Users
Ethics on DOTmed
View Our
Ethics Program
Gold Parts Vendor Program
Receive PH
Requests
Gold Service Dealer Program
Receive RFP/PS
Requests
Healthcare Providers
See all
HCP Tools
Jobs/Training
Find/Fill
A Job
Parts Hunter +EasyPay
Get Parts
Quotes
Recently Certified
View Recently
Certified Users
Recently Rated
View Recently
Certified Users
Rental Central
Rent Equipment
For Less
Sell Equipment/Parts
Get The
Most Money
Service Technicians Forum
Find Help
And Advice
Simple RFP
Get Equipment
Quotes
Virtual Trade Show
Find Service
For Equipment
Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to DOTmed.com, Inc. Copyright ©2001-2019 DOTmed.com, Inc.
ALL RIGHTS RESERVED